Urologists may be targeted in second LHRH case

Wilmington, DE-The federal government will likely pursue urologistsin a second round of investigations surrounding the fraudulent marketingand sale of luteinizing hormone-releasing hormone agonists for prostatecancer. Just how far the probe will extend remains a source of debate amonglegal experts familiar with the case.

Related Videos

Related Content

Advertisement

November 27th 2024

Final rule: Conversion factor set for 2.83% reduction in 2025

Jonathan Rubenstein, MD Mark Painter

"The final rule for 2025 poses several challenges to urology. Lobbying efforts to preserve telehealth access and the CF will continue, perhaps dragging into 2025," write Jonathan Rubenstein, MD, and Mark Painter.

March 21st 2024

Health policy in urology: 2024 AUA Advocacy Summit recap

Urology Times staff

In this episode of Speaking of Urology®, Eugene Rhee, MD, MBA, and Logan Galansky, MD, discuss key topics in health policy and recap the AUA's recent Annual Urology Advocacy Summit.

October 10th 2024

How to code for cystoscopy with litholapaxy of more than 40 bladder calculi

Jonathan Rubenstein, MD Mark Painter

"If the documentation supported the use of modifier –22, it should be appended," write Jonathan Rubenstein, MD, and Mark Painter.

August 28th 2023

How APPs can bridge the gap in urologist shortages

Urology Times staff

In this episode, Janelle Bunce, PA-C, highlights the role that advanced practice providers can play in filling the gaps created by the growing workforce shortages in urology.

September 27th 2024

UroCuff coding presents a “conundrum” for billers

Jonathan Rubenstein, MD Mark Painter

"When determining which code you should use, you must consider your Medicare carrier’s published rules and commercial payer processing policies," write Jonathan Rubenstein, MD, and Mark Painter.

August 26th 2024

ChatGPT shows promise in responding to urology patient in-basket messages

Hannah Clarke

"Generative AI technologies may play a valuable role in providing prompt, accurate responses to routine patient questions––potentially alleviating patients' concerns while freeing up clinic time and resources to address other complex tasks," says Michael Scott, MD.

Related Content

Advertisement

November 27th 2024

Final rule: Conversion factor set for 2.83% reduction in 2025

Jonathan Rubenstein, MD Mark Painter

"The final rule for 2025 poses several challenges to urology. Lobbying efforts to preserve telehealth access and the CF will continue, perhaps dragging into 2025," write Jonathan Rubenstein, MD, and Mark Painter.

March 21st 2024

Health policy in urology: 2024 AUA Advocacy Summit recap

Urology Times staff

In this episode of Speaking of Urology®, Eugene Rhee, MD, MBA, and Logan Galansky, MD, discuss key topics in health policy and recap the AUA's recent Annual Urology Advocacy Summit.

October 10th 2024

How to code for cystoscopy with litholapaxy of more than 40 bladder calculi

Jonathan Rubenstein, MD Mark Painter

"If the documentation supported the use of modifier –22, it should be appended," write Jonathan Rubenstein, MD, and Mark Painter.

August 28th 2023

How APPs can bridge the gap in urologist shortages

Urology Times staff

In this episode, Janelle Bunce, PA-C, highlights the role that advanced practice providers can play in filling the gaps created by the growing workforce shortages in urology.

September 27th 2024

UroCuff coding presents a “conundrum” for billers

Jonathan Rubenstein, MD Mark Painter

"When determining which code you should use, you must consider your Medicare carrier’s published rules and commercial payer processing policies," write Jonathan Rubenstein, MD, and Mark Painter.

August 26th 2024

ChatGPT shows promise in responding to urology patient in-basket messages

Hannah Clarke

"Generative AI technologies may play a valuable role in providing prompt, accurate responses to routine patient questions––potentially alleviating patients' concerns while freeing up clinic time and resources to address other complex tasks," says Michael Scott, MD.